While traditional biologics continue to see strong market demand, the need for emerging therapies, such as regenerative medicines, has also given rise to a burgeoning pipeline. The biopharmaceutical industry has seen significant levels of investment going into clinical-stage projects for cell therapies, gene therapies, and other regenerative medicines over the past year (1) as efforts increase to tackle the development and manufacturing hurdles for these therapies.

Find the whole article here:  BioPharm International 35 (5), by F. Mirasol

This article is taken from F. Mirasol, “Emerging Therapies Face Development Hurdles,” BioPharm International 35 (5) 10–16, 48 (2022)